The Vanguard Group Discloses Interests in Avadel Pharmaceuticals

The Vanguard Group, Inc. has made a disclosure under Form 8.3 regarding its interests in Avadel Pharmaceuticals plc. This disclosure is mandated by the Irish Takeover Panel under Rule 8.3 of the Irish Takeover Panel Act, 1997. It reveals Vanguard's involvement in relevant securities amounting to 5.67% of Avadel's US$0.01 ordinary shares, totaling 5,525,469 shares.

The form, dated October 22, 2025, confirms that The Vanguard Group holds no interests in other parties related to this offer, nor are there any cash-settled or stock-settled derivatives associated. Additionally, there are no indemnity, option arrangements, or agreements influencing these securities disclosed, supporting a straightforward position in Avadel's ordinary shares without any attached obligations or derivatives.